Search Results
You are looking at 1 - 6 of 6 items for
- Author: C. Orozco x
- Refine by access: All content x
Search for other papers by C. Orozco in
Google Scholar
PubMed
Search for other papers by T. Perkins in
Google Scholar
PubMed
Search for other papers by F. M. Clarke in
Google Scholar
PubMed
Summary. When synthetic platelet-activating factor (PAF, 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) was injected into mature female mice during dioestrus, pro-oestrus or oestrus, it induced the expression of early pregnancy factor (EPF) activity in the sera of these animals within 1 h of injection. The sera of similarly injected males, metoestrous or immature females did not display any EPF activity. The results suggest that embryo-derived PAF may be the ovum factor responsible for triggering the generation of serum EPF activity during the preimplantation stages of pregnancy.
Search for other papers by C. Orozco in
Google Scholar
PubMed
Search for other papers by I. Cock in
Google Scholar
PubMed
Search for other papers by A. V. Perkins in
Google Scholar
PubMed
Search for other papers by F. M. Clarke in
Google Scholar
PubMed
Summary. When male mouse spleen cells were incubated with a combination of platelet activating factor (PAF, 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and sera from female mice in oestrus, the cells displayed a markedly increased rosette inhibition titre (RIT) when subsequently tested in the rosette inhibition assay. Neither PAF nor oestrous mouse sera alone could induce this effect, the combined action was required. Lyso-PAF could not substitute for the PAF, nor could male mouse sera nor the sera from females in dioestrus or metoestrus substitute for the oestrous mouse serum requirement. Pro-oestrous mouse sera could replace oestrous mouse sera but were less effective in their dose–responses. Studies on the mechanism of action of the PAF and oestrous mouse serum components suggested that the PAF stimulated the production and release of soluble factors (termed S2 factors) which by themselves could induce increased RIT values when applied to fresh spleen cells. The PAF-stimulated cell populations were rendered refractory to the action of these S2 factors and did not display increased RIT values, unless oestrous mouse serum was added. This serum acted to reverse the refractory state, allowing the S2 factors to exert their effect, and so cells treated with PAF and oestrous mouse serum displayed increased RIT values.
Keywords: early pregnancy factor; platelet activating factor; rosette inhibition assay; EPF; PAF; mouse
Search for other papers by F. M. Clarke in
Google Scholar
PubMed
Search for other papers by C. Orozco in
Google Scholar
PubMed
Search for other papers by A. V. Perkins in
Google Scholar
PubMed
Search for other papers by I. Cock in
Google Scholar
PubMed
Summary. Platelet-activating factor (PAF) stimulated mouse spleen cells to release soluble factors (termed S2 factors) which were capable of inducing increased rosette inhibition titres when applied to fresh mouse spleen cells in the rosette inhibition assay. In this ability the S2 factors mimic that of pregnancy serum, an action previously ascribed to 'early pregnancy factor'. The PAF-stimulated production of these S2 factors was not influenced by inhibitors of cyclooxygenase metabolism, but was completely inhibited by the lipoxygenase inhibitors, diethyl carbamazine and nordihydroguaiaretic acid. The S2 factors had a lipid-like character in that they were extractable in organic solvents. The calcium ionophore A23187 also stimulated the production of these factors which may well be products of the lipoxygenase pathway of arachidonic acid metabolism.
Keywords: early pregnancy factor; EPF; platelet activating factor; PAF; rosette inhibition assay; eicosanoids; leukotrienes
Search for other papers by I. Q. Clark in
Google Scholar
PubMed
Search for other papers by C. Orozco in
Google Scholar
PubMed
Search for other papers by I. E. Cock in
Google Scholar
PubMed
Search for other papers by F. M. Clarke in
Google Scholar
PubMed
The effect of ammonium sulfate on the capacity of sera of pregnant animals to induce the expression of increased rosette inhibition titres in the rosette inhibition assay, that is, to express the so-called early pregnancy factor activity, was reinvestigated. The results show that the sera of pregnant mice contain low molecular mass (less than 1 kDa) moieties active in the rosette inhibition assay. Some of these moieties could be removed from the macromolecular components of sera by dialysis; however, most, or at least the most potent, of these molecules were shown to be associated with macromolecular components of the sera and were not removed by dialysis. Treatment of sera of pregnant mice with 40% ammonium sulfate released the bound low molecular mass moieties and these moieties partitioned into the supernatant fraction, whereas the macromolecular components to which they were bound partitioned into the pellet fraction. Extensive dialysis removed the low molecular mass active moieties from the supernatant fraction. The macromolecular components remaining in the supernatant retentate fraction obtained after extensive dialysis counteracted the action of the low molecular mass moieties in a dose-dependent manner in inducing increased rosette inhibition titres. However, macromolecular components in the extensively dialysed pellet fraction associated with the low molecular mass moieties in the absence of ammonium sulfate and modified their dose–response characteristics in the biological assay. The macromolecular components in the extensively dialysed pellet and supernatant retentate fractions alone could not increase rosette inhibition titres; however, when they were recombined, components in the extensively dialysed pellet retentate fraction cooperated with components in the extensively dialysed supernatant retentate fraction to allow for the expression of activity. These results are considered in the context of a new model of the system of components present in sera of pregnant mice which allow for the expression of so-called early pregnancy factor activity.
Search for other papers by C. Orozco in
Google Scholar
PubMed
Search for other papers by I. Q. Clark in
Google Scholar
PubMed
Search for other papers by I. E. Cock in
Google Scholar
PubMed
Search for other papers by F. M. Clarke in
Google Scholar
PubMed
The supernatant and pellet retentate fractions obtained from sera from pregnant mice by ammonium sulfate fractionation and extensive dialysis cannot alone induce increased rosette inhibition titres in the rosette inhibition assay. In combination, however, the mixtures can induce increased rosette inhibition titres mimicking the activity of pregnancy sera previously ascribed to the early pregnancy factor. The studies described herein demonstrated that the supernatant retentate fractions derived from sera of pregnant mice were functionally equivalent to a platelet-activating factor (PAF) or a serum stimulus because they stimulated the spleen cells used in the assay to produce active moieties and cooperated with pure thioredoxin in allowing for expression of activity. Conversely, the pellet retentate fractions obtained from sera of pregnant mice were shown to be functionally equivalent to thioredoxin in that they cooperated with a PAF stimulus to allow for the expression of increased rosette inhibition titres. The supernatant retentate fractions obtained from sera from male mice were found to be functionally equivalent to the corresponding supernatant retentate fractions obtained from sera from pregnant mice in stimulating the production of active moieties and in cooperating with thioredoxin or the pellet fractions derived from sera from pregnant mice in allowing for increased rosette inhibition titres. The pellet retentate fractions obtained from male mouse sera, however, were not functionally equivalent to either thioredoxin or the corresponding pellet retentate fractions obtained from pregnancy sera. Consideration of these data led to a basic description of the system of components in pregnancy sera which is responsible for the expression of early pregnancy factor activity.
Search for other papers by F. M. Clarke in
Google Scholar
PubMed
Search for other papers by C. Orozco in
Google Scholar
PubMed
Search for other papers by A. V. Perkins in
Google Scholar
PubMed
Search for other papers by I. Cock in
Google Scholar
PubMed
Search for other papers by K. F. Tonissen in
Google Scholar
PubMed
Search for other papers by A. J. Robins in
Google Scholar
PubMed
Search for other papers by J. R. E. Wells in
Google Scholar
PubMed
Summary. An isolated preparation from ovine placental extracts which was active in the rosette inhibition assay mimicking the activity of the so-called 'early pregnancy factor' (EPF) has been shown to contain a 12 kDa polypeptide which could be partially resolved from low-molecular-weight active moieties. N-terminal amino acid sequence analysis of the polypeptide indicated that it was ovine thioredoxin, an identification confirmed by isolation and complete sequence analysis of the corresponding cDNA. The cDNA for human thioredoxin was expressed in Escherichia coli and the recombinant protein isolated and purified. Pure recombinant thioredoxin alone did not induce the expression of increased rosette inhibition titres (RITs) when tested in the rosette inhibition assay; but, when tested in combination with cell stimuli such as platelet-activating factor (PAF) or serum, it allowed the expression of increased RITs where none was achieved in its absence. Thioredoxin acted in the assay to reverse a refractory state normally induced by these stimuli, allowing lipoxygenase-dependent moieties also induced by the stimuli to exert their effects, resulting in the expression of increased RITs. Antibodies to recombinant thioredoxin removed from pregnancy sera the capacity to induce increased RITs, i.e. to express EPF activity, thus establishing a role for thioredoxin or thioredoxin-like proteins and associated molecules in the mechanisms which allow pregnancy sera to induce increased RITs. Based on a consideration of these and other results, a new model for the study of the EPF phenomenon is presented and discussed.
Keywords: early pregnancy factor; thioredoxin; molecular definition; man; sheep; mouse
